Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Foss

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Nature Communications|July 30, 2016
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistanceC Depner, H Zum Buttel, N Böğürcü, et al.
Bone Marrow Transplantation|November 17, 2009
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantationP J Shaughnessy, B J Bolwell, K van Besien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaE Olsen, M Duvic, A Frankel, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Nature Communications|July 30, 2016
EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistanceC Depner, H Zum Buttel, N Böğürcü, et al.
Bone Marrow Transplantation|November 17, 2009
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantationP J Shaughnessy, B J Bolwell, K van Besien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaE Olsen, M Duvic, A Frankel, et al.
Pageof 8